-

Pharmanovia Appoints New General Manager for the DACH Region

  • Nassim Rima has been announced as new general manager, DACH, with over 25 years’ experience in the pharmaceutical industry
  • This important hire is key to supporting Pharmanovia’s growth in the DACH region

BASILDON, England--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has appointed Nassim Rima as General Manager, DACH.

In his role, Nassim will be responsible for growing our on the ground presence in the DACH region. He will oversee the development of our inhouse sales force while fostering strong relationships with payors, stakeholders and customers across the region.

Before joining Pharmanovia, Nassim was the Director of Sales, Biosimilar, at Fresenius Kabi, where he was responsible for restructuring the sales organisation in Germany and creating and implementing strategies for field force excellence. Prior to this Nassim was with Celltrion Healthcare Deutschland GmbH, as Head of Sales Germany, where he was responsible for the implementation of marketing strategies that supported Celltrion’s growth in Germany.

Nassim holds a degree in Biotechnology from Otto Von Guericke University, following this he furthered his education at the Anhalt University of Applied Sciences, specialising in Industrial Engineering. This combination of Biotechnology and Industrial Engineering provided him with a unique skill set that he has effectively applied throughout his career.

Nassim’s extensive experience in the pharmaceutical sector, combined with his leadership skills and strategic vision, positions him perfectly to contribute to Pharmanovia’s growth in the DACH region.

Commenting, Nicola Noya, General Manager Europe, Pharmanovia: “We are thrilled to welcome Nassim to Pharmanovia, his impressive background and accomplishments in the pharmaceutical industry make him a valuable asset to our organisation. We look forward to his contributions to growing our business and further serving customers and patients in the DACH region.”

About Pharmanovia

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.

With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.

Contacts

Alison Dyson, Director of Communications, Pharmanovia
07442 256310/ Alison.dyson@pharmanovia.com
Or pharmanovia@67health.co.uk

Pharmanovia


Release Versions

Contacts

Alison Dyson, Director of Communications, Pharmanovia
07442 256310/ Alison.dyson@pharmanovia.com
Or pharmanovia@67health.co.uk

More News From Pharmanovia

Pharmanovia Appoints Stephan Eder as Chief Executive Officer

BASILDON, England--(BUSINESS WIRE)--Pharmanovia today announced the appointment of Stephan Eder as Chief Executive Officer (CEO) of Pharmanovia, effective today. Stephan is a highly experienced leader, with over two decades leading teams and businesses in senior roles in multi-national pharma. Most recently, he served on the Executive Committee at Stada, a private equity backed company focusing on Generics, Specialty and Consumer Healthcare, in several commercial roles, most importantly as Head...

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

BASILDON, England--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its oncology portfolio with a new licensing agreement for catumaxomab, for the treatment of malignant ascites. The agreement gives Pharmanovia the exclusive rights to bring to market, catumaxomab, a first-in-class, trifunctional bi-specific monoclonal antibody, indica...

Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease

BASILDON, U.K.--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with a new licensing agreement for XADAGO® (safinamide), an add-on treatment for adult patients with idiopathic Parkinson's disease licensed by Zambon, an Italian multinational pharmaceutical company committed to innovating cure and care to make p...
Back to Newsroom